Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ.

Br J Cancer. 2013 Jan 15;108(1):9-13. doi: 10.1038/bjc.2012.523. Epub 2012 Nov 29. Review.

2.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
3.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

PMID:
11058616
4.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
5.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
6.

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?

Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.

Cancer. 1996 May 1;77(9):1854-61.

PMID:
8646685
7.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

8.

Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Rosario DJ, Bourke L.

Br J Cancer. 2013 May 28;108(10):2194. doi: 10.1038/bjc.2013.211. Epub 2013 Apr 30. No abstract available.

9.

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

Grossmann M, Zajac JD.

Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x.

PMID:
21092052
10.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

11.

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

Basaria S.

J Androl. 2008 Sep-Oct;29(5):534-9. doi: 10.2164/jandrol.108.005454. Epub 2008 Jun 20. Review.

12.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
13.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
14.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
15.

Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.

Morrison BF, Aiken WD, Reid ME.

Rev Panam Salud Publica. 2011 Jun;29(6):404-8.

16.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

17.

[Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].

Fujikawa K, Awakura Y, Okabe T, Watanabe R, Nishimura S.

Nihon Hinyokika Gakkai Zasshi. 2003 May;94(4):503-11; discussion 511-2. Japanese.

18.

Androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL.

JAMA. 2005 Jul 13;294(2):238-44. Review.

PMID:
16014598
19.

Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.

Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group.

Int J Urol. 2004 May;11(5):295-303.

20.

[Hormone therapy of locally advanced and metastatic prostate carcinoma].

RĂ¼bben H.

Praxis (Bern 1994). 2001 Sep 20;90(38):1641-4. German.

PMID:
11675917

Supplemental Content

Support Center